HRT Financial’s ProPhase Labs PRPH Stock Holding History

HRT Financial’s Portfolio PRPH Stock Details PRPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,124	Closed	-$204K	–	3048
2022 Q4	$204K	Buy	+2,124	New	+$229K	﹤0.01%	1931

Other funds holding PRPH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AWE

Avidian Wealth Enterprises Houston, Texas $3.62B AUM 24.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HRT Financial's PRPH Position: Q1 2023 in Review

HRT Financial sold out of ProPhase Labs (PRPH) in Q1 2023, closing a stake of 2,124 shares — an estimated $204K sold.

HRT Financial first reported a position in PRPH in Q4 2022 and held it in 1 quarter. The position peaked at $204K in Q4 2022. 39 funds tracked by Wall St. Rank hold PRPH as of Q1 2023.

HRT Financial reported no remaining ProPhase Labs position as of Q1 2023 after selling out during the quarter.
HRT Financial sold 2,124 ProPhase Labs shares in Q1 2023, an estimated $204K.
HRT Financial first reported a position in ProPhase Labs in Q4 2022 and held it in 1 quarter.
HRT Financial's ProPhase Labs position peaked at $204K in Q4 2022.
39 funds tracked by Wall St. Rank held ProPhase Labs as of Q1 2023.

Based on HRT Financial's 13F filing for Q1 2023, filed 12 May 2023.